secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001628280-24-045465
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience Q3 2024 FYARRO sales $7.2M (+21% YoY); net loss $12.5M
----------------------------------------------------------------------

- FYARRO net product sales of $7.2M in Q3 2024, up 17% from Q2 2024 and 21% from prior year.
- Net loss of $12.5M for Q3 2024 vs $16.3M for Q3 2023; operating expenses $20.6M incl $2.6M restructuring.
- Cash, equivalents, and short-term investments $62.6M as of Sep 30, 2024; expected to fund ops into 2H 2026.
- Completed wind-down of PRECISION1 trial; Phase 2 trials for EEC and NETs enrolled 24 and 12 patients.
- Comprehensive strategic review ongoing to maximize shareholder value; no timeline provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000162828024045465/0001628280-24-045465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000162828024045465/aadi-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer